XML 36 R25.htm IDEA: XBRL DOCUMENT
v3.25.3

Restructuring, Impairment, and Related Charges, Net (Tables) | 6 Months Ended
--- | ---
Sep. 30, 2025
Restructuring and Related Activities [Abstract] |
Schedule of Restructuring, Impairment, and Related Charges, Net | Restructuring, impairment, and related charges, net for the three months ended September 30, 2025 and 2024 consisted of the following:
| Three Months Ended September 30, 2025
(In millions) | North American Pharmaceutical (1) |  |  |  | Prescription Technology Solutions |  | Medical-Surgical Solutions (2) |  | Corporate (3) |  | Total
Severance and employee-related costs, net | $ | 4 |  |  |  |  | $ | — |  |  | $ | 5 |  |  | $ | — |  |  | $ | 9 |
Exit and other-related costs (4) | 1 |  |  |  |  | — |  |  | 14 |  |  | 37 |  |  | 52 |
Asset impairments and accelerated depreciation | 1 |  |  |  |  | — |  |  | — |  |  | 1 |  |  | 2 |
Total | $ | 6 |  |  |  |  | $ | — |  |  | $ | 19 |  |  | $ | 38 |  |  | $ | 63 |
(1)Includes costs related to operational efficiencies and cost optimization efforts described above to support the Company’s North American Pharmaceutical segment. (2)Includes costs related to operational efficiencies and cost optimization efforts described above to support the Company’s Medical-Surgical Solutions segment. (3)Includes costs related to operational efficiencies and cost optimization efforts described above to support the Company’s Corporate activities. (4)Exit and other-related costs consist of accruals for costs to be incurred without future economic benefits, project consulting fees, and other exit costs expensed as incurred.
| Three Months Ended September 30, 2024
(In millions) | North American Pharmaceutical (1) |  |  |  | Prescription Technology Solutions |  | Medical-Surgical Solutions (2) |  | Corporate |  | Total
Severance and employee-related costs, net | $ | 1 |  |  |  |  | $ | — |  |  | $ | 144 |  |  | $ | 4 |  |  | $ | 149 |
Exit and other-related costs (3) | (1) |  |  |  |  | — |  |  | 3 |  |  | 10 |  |  | 12 |
Asset impairments and accelerated depreciation | 63 |  |  |  |  | 1 |  |  | — |  |  | 9 |  |  | 73 |
Total | $ | 63 |  |  |  |  | $ | 1 |  |  | $ | 147 |  |  | $ | 23 |  |  | $ | 234 |
(1)Includes costs related to operational efficiencies and cost optimization efforts described above to support the Company’s North American Pharmaceutical segment, including an inventory impairment of $63 million within "Cost of sales" in the Condensed Consolidated Statement of Operations. (2)Includes costs related to operational efficiencies and cost optimization efforts described above to support the Company’s Medical-Surgical Solutions segment. (3)Exit and other-related costs consist of accruals for costs to be incurred without future economic benefits, project consulting fees, and other exit costs expensed as incurred. Restructuring, impairment, and related charges, net for the six months ended September 30, 2025 and 2024 consisted of the following:
| Six Months Ended September 30, 2025
(In millions) | North American Pharmaceutical (1) |  |  |  | Prescription Technology Solutions |  | Medical-Surgical Solutions (2) |  | Corporate (3) |  | Total
Severance and employee-related costs, net | $ | 4 |  |  |  |  | $ | — |  |  | $ | 10 |  |  | $ | (1) |  |  | $ | 13 |
Exit and other-related costs (4) | 2 |  |  |  |  | — |  |  | 26 |  |  | 65 |  |  | 93 |
Asset impairments and accelerated depreciation | 1 |  |  |  |  | — |  |  | — |  |  | 3 |  |  | 4 |
Total | $ | 7 |  |  |  |  | $ | — |  |  | $ | 36 |  |  | $ | 67 |  |  | $ | 110 |
(1)Includes costs related to operational efficiencies and cost optimization efforts described above to support the Company’s North American. Pharmaceutical segment. (2)Includes costs related to operational efficiencies and cost optimization efforts described above to support the Company’s Medical-Surgical Solutions segment. (3)Includes costs related to operational efficiencies and cost optimization efforts described above to support the Company’s Corporate activities. (4)Exit and other-related costs consist of accruals for costs to be incurred without future economic benefits, project consulting fees, and other exit costs expensed as incurred.
| Six Months Ended September 30, 2024
(In millions) | North American Pharmaceutical (1) |  |  |  | Prescription Technology Solutions |  | Medical-Surgical Solutions (2) |  | Corporate (3) |  | Total
Severance and employee-related costs, net | $ | 1 |  |  |  |  | $ | — |  |  | $ | 144 |  |  | $ | 3 |  |  | $ | 148 |
Exit and other-related costs (3) | (1) |  |  |  |  | 3 |  |  | 6 |  |  | 12 |  |  | 20 |
Asset impairments and accelerated depreciation | 65 |  |  |  |  | 2 |  |  | — |  |  | 9 |  |  | 76 |
Total | $ | 65 |  |  |  |  | $ | 5 |  |  | $ | 150 |  |  | $ | 24 |  |  | $ | 244 |
(1)Includes costs related to operational efficiencies and cost optimization efforts described above to support the Company’s North American Pharmaceutical segment, including an inventory impairment of $63 million within "Cost of sales" in the Condensed Consolidated Statement of Operations. (2)Includes costs related to operational efficiencies and cost optimization efforts described above to support the Company’s Medical-Surgical Solutions segment. (3)Exit and other-related costs consist of accruals for costs to be incurred without future economic benefits, project consulting fees, and other exit costs expensed as incurred.
Schedule of Activity Related to the Liabilities | The following table summarizes the activity related to the liabilities associated with the Company’s restructuring initiatives for the six months ended September 30, 2025:
(In millions) | North American Pharmaceutical |  |  |  | Prescription Technology Solutions |  | Medical-Surgical Solutions |  | Corporate |  | Total
Balance, March 31, 2025 (1) | $ | 11 |  |  |  |  | $ | 1 |  |  | $ | 90 |  |  | $ | 24 |  |  | $ | 126 |
Restructuring, impairment, and related charges, net | 7 |  |  |  |  | — |  |  | 36 |  |  | 67 |  |  | 110 |
Non-cash charges | (1) |  |  |  |  | — |  |  | — |  |  | (3) |  |  | (4) |
Cash payments | (3) |  |  |  |  | (1) |  |  | (87) |  |  | (71) |  |  | (162) |
Balance, September 30, 2025 (2) | $ | 14 |  |  |  |  | $ | — |  |  | $ | 39 |  |  | $ | 17 |  |  | $ | 70 |
(1)As of March 31, 2025, the total reserve balance was $126 million, of which $103 million was recorded within “Other accrued liabilities” and $23 million was recorded within “Other non-current liabilities” in the Company’s Condensed Consolidated Balance Sheet. (2)As of September 30, 2025, the total reserve balance was $70 million, of which $52 million was recorded within “Other accrued liabilities” and $18 million was recorded within “Other non-current liabilities” in the Company’s Condensed Consolidated Balance Sheet.

X
- References No definition available. + Details
Name: | us-gaap_RestructuringAndRelatedActivitiesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 5.P.3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1 + Details
Name: | us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1 + Details
Name: | us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration